Prognostic factors for freedom from progression: Cox proportional hazard model
| . | Relative benefit* . | CI . | P† . |
|---|---|---|---|
| 158 V/V | 4.41 | 1.90-10.25 | <.001 |
| 131 H/H | 0.68 | 0.41-1.13 | .139 |
| Humoral immune response | 2.64 | 1.57-4.42 | <.001 |
| Cellular immune response | 0.61 | 0.35-1.05 | .075 |
| CR | 2.23 | 1.36-3.64 | .001 |
| Use of adriamycin | 0.67 | 0.37-1.21 | .183 |
| Use of fludarabine | 1.27 | 0.72-2.26 | .416 |
| Stage IV | 0.69 | 0.40-1.18 | .177 |
| Clinical symptoms‡ | 1.34 | 0.63-2.86 | .453 |
| Age | 0.98 | 0.96-1.01 | .182 |
| Time from diagnosis to induction chemotherapy | 1.00 | 1.00-1.01 | .051 |
| GM-CSF adjuvant | 0.67 | 0.33-1.35 | .259 |
| High/intermediate FLIPI§ | 0.45 | 0.19-1.02 | .060 |
| . | Relative benefit* . | CI . | P† . |
|---|---|---|---|
| 158 V/V | 4.41 | 1.90-10.25 | <.001 |
| 131 H/H | 0.68 | 0.41-1.13 | .139 |
| Humoral immune response | 2.64 | 1.57-4.42 | <.001 |
| Cellular immune response | 0.61 | 0.35-1.05 | .075 |
| CR | 2.23 | 1.36-3.64 | .001 |
| Use of adriamycin | 0.67 | 0.37-1.21 | .183 |
| Use of fludarabine | 1.27 | 0.72-2.26 | .416 |
| Stage IV | 0.69 | 0.40-1.18 | .177 |
| Clinical symptoms‡ | 1.34 | 0.63-2.86 | .453 |
| Age | 0.98 | 0.96-1.01 | .182 |
| Time from diagnosis to induction chemotherapy | 1.00 | 1.00-1.01 | .051 |
| GM-CSF adjuvant | 0.67 | 0.33-1.35 | .259 |
| High/intermediate FLIPI§ | 0.45 | 0.19-1.02 | .060 |
CI indicates 95% confidence interval.
Relative benefit indicates longer freedom from progression from last chemotherapy.
All P values are 2 sided and considered to be statistically significant for P < .05.
Clinical symptoms are fever, night sweats, and weight loss.
Analyzed on 127 patients with available FLIPI score.